Real Money authors - Bret Jensen

Bret Jensen

Bret Jensen was chief investment strategist from 2008-2011 for Simplified Asset Management (S.A.M.), a small long/short hedge fund based in Miami. The fund was in top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database (more than 450 funds in category). Jensen has nearly 20 years of experience in the financial services industry, including more than a decade of managerial experience at American Express. He holds a Bachelor of Science degree in finance from Arizona State University. His personal blog is at Jensen acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. Follow Bret on Twitter: @Bret_Jensen.
Email Bret Jensen

Recent Articles By The Author

Eye-Catching Quarterly Results From a Trio of Companies

The first-quarter reports from Camping World, Esperion Therapeutics and BioDelivery Sciences were impressive amid coronavirus disruption.

Here's a Quartet of Small Biotechs That Could Make for Acquisition Targets

Merger activity is picking up this week in the biotechnology sector and these four promising companies would be good buyout candidates.

3 Promising Biotech Stocks to Buy on a Market Pullback

Eagle Pharmaceuticals, Biohaven Pharmaceuticals and Acadia Pharmaceuticals are names to consider on a 10% move down in equities.

Here's Betting a V-Shaped Recovery From Covid-19 Isn't in the Cards

Massive unemployment, reduced consumer spending and uncertainty around state reopening plans favor a U-shaped recovery from the coronavirus crisis.

2 Picks, 2 Pans Among Small-Cap Biotechs Laboring in the Covid-19 Fields

Quotient Limited and Redhill Biopharma could deliver for shareholders, while Novavax Inc. and Inovio Pharmaceuticals may not in the end.

These Stocks and Sectors Should Hold Up Well Despite Covid-19

It is worth tracking these three names.

2 Sectors That Will Look Markedly Different Under the New Normal

Retail and real estate already were undergoing change and that process only will be accelerated by differences in how we live amid the coronavirus.

2 Small Biopharma Stocks That Should Perk Up as Nation Returns to Work

Flexion Therapeutics and BioDelivery Sciences International have promising products that should do well once the fixation on Covid-19 treatments wanes.

2 Stocks That Insiders Are Buying and Simply May Be Too Good to Pass Up

Simply Good Foods and Myovant Sciences looked poised to see their shares rise over the longer term.

Maintaining Optimism in a Surreal Pandemic Environment

I never understood why my state of Florida, with vastly fewer deaths, is on the same sort of lockdown as New York.

Email sent

Thank you, your email to has been sent successfully.


We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight